The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review.
World journal of oncology 2014 Dec;5;232-236 — 2014 Dec — 232-236
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
Japanese journal of clinical oncology 2017 Apr 01;47;350-356 — 2017 Apr 01 — 350-356
Pemetrexed induced pneumonitis.
Clinics and practice 2011 Sep 28;1;e106 — 2011 Sep 28 — e106
Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.
Cancer research and treatment : official journal of Korean Cancer Association 2013 Mar;45;74-7 — 2013 Mar — 74-7
Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Chemotherapy 2012;58;84-8 — 2012 — 84-8
Pemetrexed-induced lung toxicity: a case report.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2012 Feb;24;76-7 — 2012 Feb — 76-7
Pemetrexed-induced pneumonitis: a case report.
Clinical lung cancer 2009 Sep;10;364-6 — 2009 Sep — 364-6